Skip to content

Home-Based PrEP for Youth: Enhancing HIV Prevention for Young Men who have Sex with Men and Transgender Women (Home-based PrEP)

Home-Based PrEP for Youth: Enhancing HIV Prevention for Young Men who have Sex with Men and Transgender Women (Home-based PrEP)

Status
Unknown
Phases
Unknown
Study type
Observational
Source
TCTR
Registry ID
TCTR20211022004
Enrollment
75
Registered
2021-10-22
Start date
2022-02-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV-negative, PrEP-eligible men who have sex with men and transgender women aged 18-24 years with self-reported anal intercourse in the previous six months, who from this point of the document on will be called simply YMSM and TGW. Home-Based PrEP YMSM TGW

Interventions

All study participants will receive the PrEP services at both the remote visits (telehealth) and the clinic visits (standard of care). The remote visits will be at the Month-1, 3 and 9. The clinic vis
satisfaction score will be compared between the remote and clinic visits.
Health Services Research
Participants on PrEP

Sponsors

U.S. National Institutes of Health to TREAT Asia/amfAR for the International epidemiology Database to Evaluate AIDS (IeDEA; 5U01AI069907)
Lead Sponsor
UNICEF East Asia and Pacific Regional Office
Collaborator

Eligibility

Sex/Gender
All
Age
18 Years to 24 Years

Inclusion criteria

Inclusion criteria: .. Thai nationality and male at birth. .. Aged 18 to 24 years. .. Living in Bangkok or its surrounding vicinities (Partum Thani, Samut Prakarn and Nonthaburi provinces). .. History of anal intercourse in the past 6 months. .. HIV-negative by rapid testing. .. Estimated creatinine clearance greater than or equal to 60 mL/min. .. Able to participate in the study for 12 months total and with in-person clinic visits once every 6 months. .. Able to participate in the home-based testing and remote monitoring visits at Month-1 Month-3 and Month-9.

Exclusion criteria

Exclusion criteria: Self-report of allergy to emtricitabine or tenofovir.

Design outcomes

Primary

MeasureTime frame
Safety Enrollment, Month-6 and Month-12 Creatinine clearance

Secondary

MeasureTime frame
Acceptability Screening Willing to join the study,Retention Month-6 and Month-12 Retention in study

Countries

Thailand

Contacts

Public ContactMontinee Vasantiuppapokakorn

Ministry of Public Health

dr.monthinee@gmail.com086 408 0588

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026